Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.
Section of Clinical Chemistry, University of Verona, Verona, Italy.
Biochem Med (Zagreb). 2019 Jun 15;29(2):020705. doi: 10.11613/BM.2019.020705.
No guideline currently exists on how to detect or document haemolysis, icterus or lipemia (HIL) in blood samples, nor on subsequent use of this information. The EFLM WG-PRE has performed a survey for assessing current practices of European laboratories in HIL monitoring. This second part of two coherent articles is focused on HIL.
An online survey, containing 39 questions on preanalytical issues, was disseminated among EFLM member countries. Seventeen questions exclusively focused on assessment, management and follow-up actions of HIL in routine blood samples.
Overall, 1405 valid responses from 37 countries were received. A total of 1160 (86%) of all responders stating to analyse blood samples - monitored HIL. HIL was mostly checked in clinical chemistry samples and less frequently in those received for coagulation, therapeutic drug monitoring and serology/infectious disease testing. HIL detection by automatic HIL indices or visual inspection, along with haemolysis cut-offs definition, varied widely among responders. A quarter of responders performing automated HIL checks used internal quality controls. In haemolytic/icteric/lipemic samples, most responders (70%) only rejected HIL-sensitive parameters, whilst about 20% released all test results with general comments. Other responders did not analysed but rejected the entire sample, while some released all tests, without comments. Overall, 26% responders who monitored HIL were using this information for monitoring phlebotomy or sample transport quality.
Strategies for monitoring and treating haemolytic, icteric or lipemic samples are quite heterogeneous in Europe. The WG-PRE will use these insights for developing and providing recommendations aimed at harmonizing strategies across Europe.
目前尚无关于如何检测或记录血液样本中的溶血、黄疸或脂血(HIL),以及如何随后使用这些信息的指南。EFLM WG-PRE 已对欧洲实验室进行了一项关于 HIL 监测的当前实践的调查。这两篇连贯文章的第二部分专注于 HIL。
一项包含 39 个有关分析前问题的在线调查,在 EFLM 成员国中进行了分发。其中 17 个问题专门针对常规血液样本中 HIL 的评估、管理和随访措施。
总共收到了来自 37 个国家的 1405 份有效回复。所有回复者中有 1160 人(86%)表示要分析血液样本-监测 HIL。HIL 主要在临床化学样本中检查,在凝血、治疗药物监测以及血清学/传染病检测中较少检查。HIL 的检测通过自动 HIL 指数或目视检查,以及溶血截止值的定义,在回复者之间差异很大。四分之一的执行自动 HIL 检查的回复者使用内部质量控制。在溶血/黄疸/脂血样本中,大多数回复者(70%)仅拒绝 HIL 敏感参数,而约 20%的回复者发布所有测试结果并附有一般性评论。其他回复者不进行分析,但拒收整个样本,而有些回复者发布所有测试结果,没有评论。总体而言,26%监测 HIL 的回复者正在使用这些信息来监测采血管或样本运输质量。
在欧洲,监测和处理溶血、黄疸或脂血样本的策略差异很大。WG-PRE 将利用这些见解制定和提供建议,旨在协调整个欧洲的策略。